GSK’sGSK-0.32%decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer ...

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Blenrep as a late-line option and as part ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Feel unsure about the market ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome ...

Blenrep-Vd slashed the risk of progression or death by 59% versus Darzalex-Vd. The GSK regimen also helped patients live longer, lowering the risk of death by 42% versus the Darzalex-based comparator.

The Blenrep results presented Monday are from a Phase 3 test, DREAMM-7, that enrolled nearly 500 patients whose multiple myeloma relapsed or was refractory to at least one earlier line of therapy.

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

In the study, a treatment combination including the drug, called Blenrep, cut the risk of death by 42% among patients with multiple myeloma, a result that was statistically significant and that ...

GSK said a late-stage trial of its blood-cancer drug Blenrep showed positive results. G SK’s blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma ...